| Name | Title | Contact Details |
|---|
Accurate Biomed Services is a Bethany, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Boston Scientific` we work collaboratively to solve healthcare`s toughest problems by developing solutions that matter most to those suffering from debilitating and life threatening conditions and the healthcare professionals who provide their care. Across 100+ countries` we help providers deliver care more effectively by reducing costs` increasing efficiencies and expanding access to care in order to help more people in more places live longer` healthier lives. We go beyond our mission of transforming patient lives by investing in the future and the well-being of our employees and our planet. Our commitment to sustainability is evident in our Newsweek ranking as the 16th greenest company in the U.S. We also strive to foster a diverse and inclusive work environment and provide opportunities for our 29`000+ employees around the world to serve in their local communities.
Queens Hospital Center is a Jamaica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sophion Bioscience is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.